Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CSL112 PK/Safety in Moderate Renal Impairment
NCT02427035Phase 1Completed
- Sponsor
- CSL Limited
- Start
- May 2015
- Primary completion
- Nov 2015
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of CSL112 in acute myocardial infarction (AMI) (2 arms), sponsored by CSL Limited. Primary endpoints: Plasma apolipoprotein A-I and phosphatidylcholine Area Under the Curve up to 7 days, Plasma apolipoprotein A-I and phosphatidylcholine Maximum Concentration up to 7 days and 4 more. Started May 2015; status: completed.
02
Drugs
CSL112
03
Conditions
acute myocardial infarction (AMI)
Beyond the preview
Go deeper on NCT02427035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02427035.